During discovery and early development of antibodies, thousands of antibodies are screened and evaluated in several cycles, to arrive at a clinical lead candidate. The lead candidate has the desired functional properties and ideally developability aspects have been considered to facilitate manufacturing and to avoid pitfalls in clinical studies. In the recent white paper, Biacore™ systems in discovery and early-stage development of biotherapeutic antibodies, I have tried to describe how Biacore instruments, software, sensor chips and kits support the execution and evaluation of a number of different screening and characterization assays. The paper is quite short and consists of 10 pages of text and figures and includes 40 references to relevant topics. It is included as an attachment.GE-Robert